** Shares of drug developer Biohaven Ltd BHVN.N fall 14.4% to $39.02 premarket
** BHVN says its experimental drug, taldefgrobep alfa, did not meet the main goal of improving muscle function in patients with a rare neuromuscular disorder called spinal muscular atrophy in a late-stage study
** Taldefgrobep alfa is designed to block myostatin, a protein that limits muscle growth, which helps increase muscle mass and improve muscle function
** However, the drug showed positive effects on body composition, such as reducing fat mass, supporting its potential as an obesity treatment, co says
** As of last close, stock has risen 6.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。